Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Autor: William Pao, Malcolm R. Ranson, Dong-Wan Kim, Mireille Cantarini, Graham H.P. Richmond, Teresa Klinowska, Rachel Rowlinson, Katherine Al-Kadhimi, Peter Ballard, Hailing Jin, Jing Sun, Eiki Ichihara, Monica Red Brewer, Vivien N. Jacobs, Amar Rahi, Gareth Hughes, Martine J. Mellor, Richard A. Ward, M. Raymond V. Finlay, Jonathon P. Orme, Paula J. Spitzler, Caroline A. Nebhan, Cath Eberlein, Serban Ghiorghiu, Susan E. Ashton, Darren A.E. Cross

PDF file - 235KB, Activity of AZD9291 and metabolites against rare EGFR mutations using cellular phosphorylation assays.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aae9b7c4ff971c9197748ea7ba30b12d
https://doi.org/10.1158/2159-8290.22532204

Supplementary Figure 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Autor: William Pao, Malcolm R. Ranson, Dong-Wan Kim, Mireille Cantarini, Graham H.P. Richmond, Teresa Klinowska, Rachel Rowlinson, Katherine Al-Kadhimi, Peter Ballard, Hailing Jin, Jing Sun, Eiki Ichihara, Monica Red Brewer, Vivien N. Jacobs, Amar Rahi, Gareth Hughes, Martine J. Mellor, Richard A. Ward, M. Raymond V. Finlay, Jonathon P. Orme, Paula J. Spitzler, Caroline A. Nebhan, Cath Eberlein, Serban Ghiorghiu, Susan E. Ashton, Darren A.E. Cross

PDF file - 107KB, Mass Spectrometry study showing covalent binding of AZD9291 to cysteine 797 in EGFR T790M.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fee71280bb8e5903ad324190bd450d
https://doi.org/10.1158/2159-8290.22532210.v1

Supplementary Figure 7 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Autor: William Pao, Malcolm R. Ranson, Dong-Wan Kim, Mireille Cantarini, Graham H.P. Richmond, Teresa Klinowska, Rachel Rowlinson, Katherine Al-Kadhimi, Peter Ballard, Hailing Jin, Jing Sun, Eiki Ichihara, Monica Red Brewer, Vivien N. Jacobs, Amar Rahi, Gareth Hughes, Martine J. Mellor, Richard A. Ward, M. Raymond V. Finlay, Jonathon P. Orme, Paula J. Spitzler, Caroline A. Nebhan, Cath Eberlein, Serban Ghiorghiu, Susan E. Ashton, Darren A.E. Cross

PDF file - 470KB, Effect of AZD9291 and AZ5104 in transgenic models of EGFR-TKI sensitizing (C/L858R and C/ex19del) and T790M resistant (C/L+T) lung cancer.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d10f5fe0ea84a79486aa4e5b07fa2aed
https://doi.org/10.1158/2159-8290.22532192.v1

Supplementary Table 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Autor: William Pao, Malcolm R. Ranson, Dong-Wan Kim, Mireille Cantarini, Graham H.P. Richmond, Teresa Klinowska, Rachel Rowlinson, Katherine Al-Kadhimi, Peter Ballard, Hailing Jin, Jing Sun, Eiki Ichihara, Monica Red Brewer, Vivien N. Jacobs, Amar Rahi, Gareth Hughes, Martine J. Mellor, Richard A. Ward, M. Raymond V. Finlay, Jonathon P. Orme, Paula J. Spitzler, Caroline A. Nebhan, Cath Eberlein, Serban Ghiorghiu, Susan E. Ashton, Darren A.E. Cross

PDF file - 89KB, Additional biochemical and cellular profiling data for AZD9291 and metabolites.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d76504690708d6ace2f513b9760d1d9
https://doi.org/10.1158/2159-8290.22532189.v1

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours

Autor: N Cresti, Karen E Swales, Mark Merriman, Rodger A. Allen, Paul Bevan, Carola Mala, Richard H. Wilson, Alan V. Boddy, Malcolm R Ranson, T. R. Jeffery Evans, Alastair Greystoke, Vicky M. Coyle, Ruth Plummer, Yvette Drew, Julieann Sludden, Alan Anthoney, Lisa Jane Rodgers, MJ Griffin, David Jamieson, Udai Banerji, Emma Dean, Markus Buerkle

Publikováno v: Jamieson, D, Griffin, M, Sludden, J, Drew, Y, Cresti, N, Swales, K, Merriman, M, Allen, R, Bevan, P, Buerkle, M, Mala, C, Coyle, V, Rodgers, L, Dean, E, Greystoke, A, Banerji, U, Wilson, R, Evans, J, Anthoney, A, Ranson, M, Boddy, A & Plummer, R 2016, ' A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours ', European Journal of Cancer, vol. 68 . https://doi.org/10.1016/j.ejca.2016.08.026
Jamieson, D, Griffin, M J, Sludden, J, Drew, Y, Cresti, N, Swales, K, Merriman, M, Allen, R, Bevan, P, Buerkle, M, Mala, C, Coyle, V, Rodgers, L, Dean, E, Greystoke, A, Banerji, U, Wilson, R H, Evans, T R J, Anthoney, A, Ranson, M, Boddy, A V & Plummer, R 2016, ' A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours ', European Journal of Cancer, vol. 68, pp. 1-10 . https://doi.org/10.1016/j.ejca.2016.08.026

Purpose:\ud \ud We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cfeb7e3462ba1cdff56aeaf39e4fa01
https://doi.org/10.1016/j.ejca.2016.08.026